2021
DOI: 10.3390/antiox10121920
|View full text |Cite
|
Sign up to set email alerts
|

Nephroprotective Effects of Synthetic Flavonoid Hidrosmin in Experimental Diabetic Nephropathy

Abstract: Diabetes mellitus (DM) is a high-impact disease commonly characterized by hyperglycemia, inflammation, and oxidative stress. Diabetic nephropathy (DN) is a common diabetic microvascular complication and the leading cause of chronic kidney disease worldwide. This study investigates the protective effects of the synthetic flavonoid hidrosmin (5-O-(beta-hydroxyethyl) diosmin) in experimental DN induced by streptozotocin injection in apolipoprotein E deficient mice. Oral administration of hidrosmin (300 mg/kg/day,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
8
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(9 citation statements)
references
References 71 publications
1
8
0
Order By: Relevance
“…ApoE KO mice (14–16 weeks old males; Jackson Laboratory, Bar Harbor, ME, USA) were made diabetic by two daily consecutive injections of STZ (125 mg/kg/day, intraperitoneally; S0130, Sigma-Aldrich, St. Louis, MO, USA) dissolved in 10 mmol/L citrate buffer pH 4.5 [ 32 , 33 ]. After 2 weeks, mice with overt diabetes (glucose > 350 mg/dL) were randomized to receive 300 mg/kg/day of hidrosmin in the drinking water (D group, n = 11) or tap water (D + H group, n = 7) for 7 weeks, based on our previous study [ 30 ].…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…ApoE KO mice (14–16 weeks old males; Jackson Laboratory, Bar Harbor, ME, USA) were made diabetic by two daily consecutive injections of STZ (125 mg/kg/day, intraperitoneally; S0130, Sigma-Aldrich, St. Louis, MO, USA) dissolved in 10 mmol/L citrate buffer pH 4.5 [ 32 , 33 ]. After 2 weeks, mice with overt diabetes (glucose > 350 mg/dL) were randomized to receive 300 mg/kg/day of hidrosmin in the drinking water (D group, n = 11) or tap water (D + H group, n = 7) for 7 weeks, based on our previous study [ 30 ].…”
Section: Methodsmentioning
confidence: 99%
“…Besides the treatment of chronic venous insufficiency, several preclinical studies have established that diosmin-containing medicinal products protect against hepatic, pulmonary, neurological, gastrointestinal, myocardial and renal injuries [ 23 , 24 , 25 , 29 ]. In this line, our previous study was the first to demonstrate a favorable effect of hidrosmin on the reduction of renal damage in diabetic mice [ 30 ]; however, the mechanisms and actions of the synthetic flavonoid in macrovascular complications of diabetes have not been scrutinized.…”
Section: Introductionmentioning
confidence: 99%
“…With the rapidly increasing incidence worldwide, it is estimated that the number of diabetic patients will reach 300 million by 2025 [ 2 ]. Among them, about one-third of diabetes later developed into diabetic nephropathy, which is the main cause of end-stage renal disease (ESRD) [ 3 ]. At present, there is no clear etiology and pathogenesis of DN, which leads to limitations in the clinical treatment of DN [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
“…Among them, about one-third of diabetes later developed into diabetic nephropathy, which is the main cause of end-stage renal disease (ESRD) [ 3 ]. At present, there is no clear etiology and pathogenesis of DN, which leads to limitations in the clinical treatment of DN [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
“… 12 It has been reported that there are high concentrations of inflammatory cells in the glomeruli and tubulointerstitium of diabetic kidneys, as well as the overexpression of chemokines, cytokines and adhesion molecules, and inflammation has become a focus of DKD development. 13 We will also focus on the relationship between diabetic nephropathy and inflammation in this study.…”
Section: Introductionmentioning
confidence: 99%